FTC, PBMs
Pharmacy benefit managers respond to FTC's lawsuit over insulin drug prices
CNBC's Eamon Javers joins 'The Exchange' to report the latest on the FTC's lawsuit against drug middlemen for allegedly inflating insulin prices.
FTC Sues Pharmacy Middlemen For Allegedly Inflating Insulin Prices
Months earlier, the agency released a report alleging the companies drove up the costs of some medications, including insulin.
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health Inc’s (NYSE:CVS) Caremark, Cigna Corp’s (NYSE:CI) Express Scripts,
UnitedHealth, CVS Caremark, Express Scripts sued by FTC over skyrocketing insulin prices
The FTC sued UnitedHealth Group’s Optum unit, CVS Caremark and Cigna’s Express Scripts for allegedly steering diabetes patients towards higher priced insulin.
FTC sues over allegedly inflated insulin prices
The federal government is suing some big pharmacy benefit managers over a system of drug rebates that regulators say has made the price of insulin soar for diabetic patients.
FTC sues major pharmacy benefit managers over insulin prices
The agency brought action against Caremark, Express Scripts and Optum Rx on Friday, arguing their “anticompetitive and unfair” rebating practices “artificially inflated” the list price of life-saving insulin drugs.
American Pharmacists Association applauds FTC action on PBMs' alleged inflation of insulin drug prices
Hogue, PharmD, FAPhA, FNAP, FFIP, executive vice president and CEO of APhA, commended the Federal Trade Commission's (FTC) action today against alleged practices by large vertically integrated pharmacy benefit managers (PBMs) "for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs,
UnitedHealth, Cigna, CVS PBMs targeted by FTC over inflated insulin prices
The Federal Trade Commission has brought an administrative complaint against three of the country's largest pharmacy benefit managers (PBMs), accusing them of engaging in practices that artificially inflated the list price of insulin drugs.
FTC targets three biggest PBMs over insulin rebates
The Federal Trade Commission's administrative complaint follows an interim report from the agency regarding PBM practices.
High insulin prices spur a federal lawsuit against three pharmacy benefit managers
Three companies that process about 80% of prescriptions in the United States — Caremark, Express Scripts and OptumRx — have ...
Axios Vitals on MSN3d
Express Scripts sues FTC over report about pharmacy benefit managers
Cigna's Express Scripts filed a lawsuit Tuesday challenging a federal report that places the blame for rising drug prices on ...
fox13now14h
FTC sues pharmaceutical middlemen, claiming practices inflated insulin cost
The Federal Trade Commission Friday announced it was suing the country's three biggest pharmacy benefit managers, claiming ...
Federal regulators sue three pharmacy benefit managers over high insulin prices
The Federal Trade Commission said the three companies' practices have artificially inflated list prices for insulin.
Express Scripts sues FTC over report blasting pharmacy middlemen
Express Scripts, one of the country’s largest pharmacy benefit managers, sued the Federal Trade Commission (FTC) Tuesday and ...
STAT3d
Express Scripts sues FTC over a ‘biased’ report about pharmacy benefit managers
Express Scripts, one of the largest pharmacy benefit managers in the U.S., filed a lawsuit demanding that a recent FTC report ...